Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/352567
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Ocio, Enrique M. | es_ES |
dc.contributor.author | Montes, Carmen | es_ES |
dc.contributor.author | Bustamante, Gabriela | es_ES |
dc.contributor.author | Garzón, Sebastián | es_ES |
dc.contributor.author | González, Esther | es_ES |
dc.contributor.author | Pérez-Persona, Ernesto | es_ES |
dc.contributor.author | González-Calle, Verónica | es_ES |
dc.contributor.author | Sirvent, Maialen | es_ES |
dc.contributor.author | Arguiñano, José M. | es_ES |
dc.contributor.author | González, Yolanda | es_ES |
dc.contributor.author | Ríos, Rafael | es_ES |
dc.contributor.author | Miguel Llorente, Dunia de | es_ES |
dc.contributor.author | Grande, Marta | es_ES |
dc.contributor.author | Fernández-Nistal, Alonso | es_ES |
dc.contributor.author | Naves, Andrea | es_ES |
dc.contributor.author | Rosiñol, Laura | es_ES |
dc.date.accessioned | 2024-04-03T07:44:29Z | - |
dc.date.available | 2024-04-03T07:44:29Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.citation | Clinical Lymphoma, Myeloma and Leukemia 23(10): e341-e347 (2023) | es_ES |
dc.identifier.issn | 2152-2650 | - |
dc.identifier.uri | http://hdl.handle.net/10261/352567 | - |
dc.description.abstract | [Background]: Most patients with multiple myeloma (MM) relapse or become refractory, resulting in high health care costs. However, real-world data regarding the utilization of health care services among the relapsed/refractory MM (RRMM) population are scarce. | es_ES |
dc.description.abstract | [Methods]: Observational, cross-sectional, multicenter study of the utilization of health care services by RRMM patients who had relapsed within the previous 6 months in Spain in a real-world setting. Data were collected from the clinical records and during a single structured interview and included sociodemographic and clinical characteristics at last relapse, the treatment and health care services nature, and were presented using descriptive statistics. | es_ES |
dc.description.abstract | [Results]: The 276 patients enrolled (53.3% males), with a mean [SD] age of 67.4 [10.5] years, had experienced their most recent relapse a median (IQR) of 1.61 (0.74, 3.14) months before entering the study. Patients lived a median (IQR) of 9.0 (3.0, 30.0) km away from the hospital and visited the hospital a median (IQR) of 3.0 (2.0, 5.0) times/month to receive treatment for their most recent relapse. They spent a median (IQR) of 15.84 (5.0, 42.0) euros/month on transportation. Since their most recent relapse, most patients had been admitted to a hospital unit (n = 155, 56.2%), had required ≥1 diagnostic tests (n = 227, 82.2%), and had consulted the hematologist (n = 270, 97.8%) a mean (SD) of 5.5 (5.4) times. In half of the visits, patients were accompanied by an actively working caregiver (n = 112, 54.4%). | es_ES |
dc.description.abstract | [Conclusions]: RRMM treatments are associated with a high utilization of health care services and pose a significant burden for patients and caregivers. | es_ES |
dc.description.sponsorship | The study was sponsored and funded by Takeda Farmacéutica España. | es_ES |
dc.format | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.relation.isversionof | Publisher's version | es_ES |
dc.relation.isbasedon | The underlying dataset has been published as supplementary material of the article in the publisher platform at 10.1016/j.clml.2023.07.006 | - |
dc.rights | openAccess | es_ES |
dc.subject | Burden | es_ES |
dc.subject | Cost of illness | es_ES |
dc.subject | Multiple myeloma | es_ES |
dc.subject | Therapy | es_ES |
dc.subject | Monoclonal gammopathy | es_ES |
dc.title | Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.1016/j.clml.2023.07.006 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.clml.2023.07.006 | es_ES |
dc.rights.license | https://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.contributor.funder | Takeda Pharmaceutical Company | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/100008373 | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Real-World Health Care_Ocio_Art_2023.pdf | 340,61 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
1
checked on 20-may-2024
Page view(s)
23
checked on 19-may-2024
Download(s)
3
checked on 19-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons